Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sunitinib therapy in metastatic papillary thyroid cancer.
Gori S, Foglietta J, Rossi M, Hamzaj A, Stocchi L, Galuppo C, Picece V, Puxeddu E, Furlani L. Gori S, et al. Among authors: foglietta j. Tumori. 2013 Nov-Dec;99(6):285e-7e. doi: 10.1700/1390.15470. Tumori. 2013. PMID: 24503805
Lung cancer.
Crinò L, Foglietta J, Hamzaj A. Crinò L, et al. Among authors: foglietta j. J Thorac Oncol. 2007 May;2(5 Suppl):S24-6. doi: 10.1097/01.JTO.0000268637.10332.e3. J Thorac Oncol. 2007. PMID: 17457226 Free article. Review. No abstract available.
Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer.
Gori S, Montemurro F, Spazzapan S, Metro G, Foglietta J, Bisagni G, Ferzi A, Silva RR, Gamucci T, Clavarezza M, Stocchi L, Fabi A, Cognetti F, Torrisi E, Crivellari D. Gori S, et al. Among authors: foglietta j. Ann Oncol. 2012 Jun;23(6):1436-41. doi: 10.1093/annonc/mdr474. Epub 2011 Oct 29. Ann Oncol. 2012. PMID: 22039084 Free article.
Efficacy of trastuzumab in unselected patients with HER2-positive metastatic breast cancer: a retrospective analysis.
Collovà E, Ferzi A, Scandurra G, Aurilio G, Torri V, Porcu L, Sanò MV, Taibi E, Foglietta J, Generali D, Andreis D, Dazzani MC, Bramati A, Marcon I, Atzori F, Cinieri S, Tondulli L, Grasso D, Nolè F, Petrella MC, Gori S, La Verde N. Collovà E, et al. Among authors: foglietta j. Tumori. 2014 Jul-Aug;100(4):426-31. doi: 10.1700/1636.17902. Tumori. 2014. PMID: 25296592
EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.
Gori S, Sidoni A, Colozza M, Ferri I, Mameli MG, Fenocchio D, Stocchi L, Foglietta J, Ludovini V, Minenza E, De Angelis V, Crinò L. Gori S, et al. Among authors: foglietta j. Ann Oncol. 2009 Apr;20(4):648-54. doi: 10.1093/annonc/mdn681. Epub 2009 Feb 2. Ann Oncol. 2009. PMID: 19188134 Free article.
Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence.
Bogina G, Lunardi G, Coati F, Zamboni G, Gori S, Bortesi L, Marconi M, Cassandrini PA, Turazza M, Cortesi L, DeMatteis E, Ficarra G, Ibrahim T, Serra P, Medri L, Giraudi S, Lambertini M, Carli F, Foglietta J, Sidoni A, Nunzi M, Ficorella C, Diadema MR, Del Mastro L. Bogina G, et al. Among authors: foglietta j. Tumori. 2015 Jul-Aug;101(4):398-403. doi: 10.5301/tj.5000323. Epub 2015 May 22. Tumori. 2015. PMID: 26045108
Adherence to oral hormonal anticancer agents in breast cancer.
Gori S, Modena A, Foglietta J, Verzè M, Inno A, Casarin A, Russo A, Nicolis F. Gori S, et al. Among authors: foglietta j. Tumori. 2023 Jun;109(3):262-268. doi: 10.1177/03008916221096183. Epub 2022 May 21. Tumori. 2023. PMID: 35603579 Review.
40 results